A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
732actual
Sites
210
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-09-30 | actual | When the study began enrolling |
| Primary completion | 2026-07-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-09 | estimated | The whole study's end, after follow-up |
| First posted | 2019-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: Nivolumab
- Drug: Ipilimumab
- Drug: Sorafenib
- Drug: lenvatinib
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 4 years
Publications
- PMID 41981891 — linked by the registry
- PMID 40349714 — linked by the registry
- PMID 38038862 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed